Nivolumab and ipilimumab in patients with dMMR and/or MSI metastatic colorectal cancer resistant to anti-PD1 monotherapy: An open-label phase II GERCOR trial (NIPIRESCUE)

2024-516313-20-00 Protocol NIPIRESCUE_G-113 Therapeutic exploratory (Phase II) Ongoing, recruiting

Start 19 Apr 2022 · Status Ongoing, recruiting · 1 EU/EEA countries · 9 sites · Protocol NIPIRESCUE_G-113

Overview

Sponsor-declared trial summary

Phase Therapeutic exploratory (Phase II)
Status Ongoing, recruiting
Participants planned 30
Countries 1
Sites 9

Metastatic colorectal cancer

Key facts

Sponsor
Association Gercor
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
19 Apr 2022 → ongoing
Decision date (initial)
2024-10-07
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-516313-20-00
EudraCT number
2021-005146-15
ClinicalTrials.gov
NCT05310643

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Metastatic colorectal cancer

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Association Gercor

7 Total trials 3 Recruiting
Academic / Non-commercial
Sponsor organisation
Association Gercor
Address
151 Rue Du Faubourg Saint Antoine
City
Paris
Postcode
75011
Country
France

Scientific contact point

Organisation
Association Gercor
Contact name
Marie-line GARCIA LARNICOL

Public contact point

Organisation
Association Gercor
Contact name
Nelly ROLDAN

Locations

1 EU/EEA country · 9 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruiting 30 9
Rest of world 0

Investigational sites

France

9 sites · Ongoing, recruiting
CHU Besancon
Oncology, 3 Boulevard Alexander Fleming, Cs 81816, Besancon Cedex
Institut Regional Du Cancer De Montpellier
Oncology, 208 Avenue Des Apothicaires, 34090, Montpellier
Centre Antoine Lacassagne
Oncology, 33 Avenue De Valombrose, 06189, Nice Cedex 2
Centre Hospitalier Et Universitaire De Limoges
Oncology, 2 Avenue Martin Luther King, 87000, Limoges
Centre Hospitalier Universitaire De Lille
Oncology, Rue Michel Polonovski, 59037, Lille Cedex
Institut Bergonie
Oncology, 180 R De Saint Genes, 229 Cours De L Argonne, Bordeaux
Hopital Saint Antoine
Oncology, 184 Rue Du Faubourg Saint Antoine, 75571, Paris Cedex 12
Centre Hospitalier Universitaire De Poitiers
Oncology, 2 Rue De La Miletrie, 86000, Poitiers
Centre De Recherche En Cancerologie De Lyon
Oncology, 28 Rue Laennec, 69008, Lyon

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2022-04-19 2022-04-19

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-08-23 France Acceptable
2024-10-07
2024-10-07
2 SUBSTANTIAL MODIFICATION SM-1 2024-12-06 France Acceptable
2025-02-06
2025-02-13
3 SUBSTANTIAL MODIFICATION SM-2 2025-12-03 France Acceptable
2026-03-09
2026-03-13